Indian (NIFTY) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Has the Indian Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 17 Jun 2026	₹3.3t	₹361.7b	₹46.4b	39.5x	70.9x	9.1x
Fri, 15 May 2026	₹3.3t	₹354.9b	₹44.7b	32.7x	74.8x	9.4x
Sun, 12 Apr 2026	₹3.0t	₹350.2b	₹46.2b	29.8x	64.2x	8.5x
Tue, 10 Mar 2026	₹2.9t	₹350.2b	₹46.2b	28.3x	63.8x	8.4x
Thu, 05 Feb 2026	₹2.8t	₹345.1b	₹46.0b	28.9x	61.3x	8.2x
Sat, 03 Jan 2026	₹3.1t	₹342.6b	₹48.4b	33.3x	64.6x	9.1x
Mon, 01 Dec 2025	₹3.1t	₹342.6b	₹48.4b	33x	64x	9x
Wed, 29 Oct 2025	₹3.2t	₹331.4b	₹45.5b	44.4x	70.3x	9.6x
Fri, 26 Sep 2025	₹3.1t	₹331.4b	₹45.5b	46.7x	68.8x	9.4x
Sun, 24 Aug 2025	₹3.2t	₹331.4b	₹45.5b	40.9x	70.6x	9.7x
Tue, 22 Jul 2025	₹3.3t	₹319.5b	₹41.7b	53.8x	79.4x	10.4x
Thu, 19 Jun 2025	₹2.8t	₹299.7b	₹37.2b	46.7x	76.5x	9.5x
Sat, 17 May 2025	₹2.7t	₹294.5b	₹32.8b	49.8x	82.7x	9.2x
Mon, 14 Apr 2025	₹2.5t	₹287.4b	₹30.8b	43.3x	80.3x	8.6x
Wed, 12 Mar 2025	₹2.5t	₹287.4b	₹30.8b	48x	80.1x	8.6x
Fri, 07 Feb 2025	₹2.7t	₹286.4b	₹31.3b	46.6x	86.4x	9.4x
Sun, 05 Jan 2025	₹2.6t	₹269.1b	₹30.1b	55.4x	85.9x	9.6x
Tue, 03 Dec 2024	₹2.5t	₹254.2b	₹28.8b	54.4x	87.4x	9.9x
Thu, 31 Oct 2024	₹2.4t	₹247.9b	₹26.0b	49.4x	91.5x	9.6x
Sat, 28 Sep 2024	₹2.3t	₹247.6b	₹26.3b	49.6x	86.7x	9.2x
Mon, 26 Aug 2024	₹2.1t	₹247.1b	₹23.8b	38.2x	87.9x	8.5x
Wed, 24 Jul 2024	₹1.8t	₹201.9b	₹23.9b	37.5x	75x	8.9x
Fri, 21 Jun 2024	₹1.7t	₹194.5b	₹21.5b	33.8x	81x	9x
Sun, 19 May 2024	₹1.6t	₹193.9b	₹21.6b	34.7x	73x	8.1x
Tue, 16 Apr 2024	₹1.4t	₹168.5b	₹18.6b	29.1x	76x	8.4x
Thu, 14 Mar 2024	₹1.3t	₹168.5b	₹18.6b	28.2x	70.8x	7.8x
Sat, 10 Feb 2024	₹1.4t	₹167.1b	₹19.0b	33.1x	74x	8.4x
Mon, 08 Jan 2024	₹1.5t	₹155.9b	₹18.1b	23.8x	80.8x	9.4x
Wed, 06 Dec 2023	₹1.4t	₹155.9b	₹18.1b	22.5x	76.2x	8.8x
Fri, 03 Nov 2023	₹1.2t	₹156.0b	₹19.8b	23.4x	63.2x	8x
Sun, 01 Oct 2023	₹1.4t	₹154.7b	₹19.7b	26.4x	71.8x	9.1x
Tue, 29 Aug 2023	₹1.4t	₹154.7b	₹19.7b	27.4x	69.3x	8.8x
Thu, 27 Jul 2023	₹1.4t	₹156.5b	₹23.0b	30.9x	59.6x	8.8x
Sat, 24 Jun 2023	₹1.3t	₹157.2b	₹23.0b	28.5x	56.2x	8.2x

Current Industry PE

Investors are pessimistic on the Indian Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 70.9x which is lower than its 3-year average PE of 74.1x.

The industry is trading close to its 3-year average PS ratio of 9.0x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have grown 26% per year over the last three years.
Revenues for these companies have grown 32% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Indian Clinical Research and Equipment compare with similar industries?


IN Market	2.23%
Healthcare	-0.17%
Life Sciences	-0.60%
Clinical Research and Equipment	-0.60%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
DIVISLAB Divi's Laboratories	₹6.66k	0.4% +₹6.6b	1.7%	PE68.9x
SAILIFE Sai Life Sciences	₹1.21k	2.1% +₹5.4b	64.3%	PE73.8x
TARSONS Tarsons Products	₹278.11	34.5% +₹3.8b	-25.6%	PE103.3x
INNOVACAP Innova Captab	₹934.90	2.7% +₹1.4b	9.5%	PE38x
524394 Vimta Labs	₹544.35	4.6% +₹1.1b	13.5%	PE31.4x

New minor risk - Dividend sustainability

The company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.4% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Share price has been volatile over the past 3 months (9.1% average weekly change). Profit margins are more than 30% lower than last year (8.9% net profit margin). Market cap is less than US$100m (₹7.37b market cap, or US$77.3m).

Indian (NIFTY) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Tarsons Products Limited Announces Resignation of Subhra Shankar Bose from Head - HR, Effective June 15, 2026

Upcoming dividend of ₹2.00 per share

Full year 2026 earnings: EPS and revenues exceed analyst expectations

DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook

SYNGENE: New Drug Manufacturing Partnership Will Support Future Earnings

INDGN: Tax Resolution Path And Dividend Prospects Will Drive Future Upside

New major risk - Financial position

Full year 2026 earnings released: EPS: ₹31.60 (vs ₹29.19 in FY 2025)

New major risk - Share price stability

Full year 2026 earnings released: EPS: ₹3.89 (vs ₹3.02 in FY 2025)

There May Be Reason For Hope In Akums Drugs and Pharmaceuticals' (NSE:AKUMS) Disappointing Earnings

Sai Life Sciences (NSE:SAILIFE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Anthem Biosciences Limited announces Annual dividend, payable on August 21, 2026

Full year 2026 earnings released: ₹12.13 loss per share (vs ₹7.37 loss in FY 2025)

New major risk - Financial position

New minor risk - Dividend sustainability